Table 4.

Key Ongoing and Planned Erlotinib Trials in Non–Small-Cell Lung Cancer (NSCLC)

Study	Setting
Adjuvant
RADIANT	Adjuvant use in patients with EGFR FISH-positive or IHC-positive status
First-line advanced
SATURN	Maintenance use
IFCT–GFPC 05.02	Maintenance use in patients with PS 0–1
TORCH	Sequential erlotinib plus chemotherapy
Spanish Lung Cancer Group	Use in patients with EGFR mutations
Second-line advanced
TITAN	Biomarker assessment with second-line erlotinib vs. chemotherapy
MARVEL	Biomarker assessment with second-line erlotinib vs. pemetrexed
Combination use
ATLAS	Maintenance use (bevacizumab plus erlotinib) in first-line advanced NSCLC

EGFR = epidermal growth factor receptor; FISH = fluorescence in situ hybridization; IHC = immunohistochemistry; PS = performance status.

Trials: ATLAS = A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy with or without Erlotinib after Completion of Chemotherapy with Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic NSCLC; IFCT–GFPC = A Randomized phase 3 Trial Assessing in Patients with Advanced NSCLC Not Progressing on First-Line Cisplatin–Gemcitabine Chemotherapy Maintenance Chemotherapy with Gemcitabine or Sequential Treatment with Erlotinib; MARVEL = Marker Validation for Erlotinib in Lung Cancer; RADIANT = A Study of Tarceva after Surgery with or without Adjuvant Chemotherapy in NSCLC Patients Who Have EGFR-Positive Tumors (Adjuvant); SATURN = Sequential Tarceva in Unresectable NSCLC; TITAN = Tarceva in Treatment of Advanced NSCLC; TORCH = Tarceva or Chemotherapy for the Treatment of Advanced NSCLC.